Anavex Life Sciences (NASDAQ:AVXL) Stock Crosses Below Fifty Day Moving Average – Should You Sell?

Anavex Life Sciences Corp. (NASDAQ:AVXL) passed below its fifty day moving average during trading on Friday . The stock has a fifty day moving average of $3.06 and traded as low as $2.56. Anavex Life Sciences shares last traded at $2.57, with a volume of 941,537 shares changing hands.

Analyst Ratings Changes

Several brokerages have commented on AVXL. HC Wainwright reissued a “buy” rating and issued a $20.00 target price on shares of Anavex Life Sciences in a research note on Tuesday, February 10th. Wall Street Zen upgraded shares of Anavex Life Sciences from a “sell” rating to a “hold” rating in a report on Saturday, February 14th. Weiss Ratings upgraded shares of Anavex Life Sciences from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, May 27th. D. Boral Capital restated a “buy” rating and set a $24.00 price objective on shares of Anavex Life Sciences in a report on Tuesday, March 31st. Finally, Rodman & Renshaw started coverage on shares of Anavex Life Sciences in a report on Monday, May 4th. They set a “buy” rating and a $20.00 price objective on the stock. Three analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $21.33.

Anavex Life Sciences Stock Performance

The stock has a market cap of $238.16 million, a P/E ratio of -5.59 and a beta of 1.20. The stock’s fifty day simple moving average is $3.06 and its 200-day simple moving average is $3.81.

Institutional Investors Weigh In On Anavex Life Sciences

Institutional investors have recently modified their holdings of the company. State of Wyoming bought a new position in Anavex Life Sciences during the second quarter worth $26,000. AlphaQuest LLC bought a new stake in Anavex Life Sciences during the third quarter valued at approximately $29,000. Quarry LP bought a new stake in Anavex Life Sciences during the third quarter valued at approximately $36,000. HBW Advisory Services LLC purchased a new position in shares of Anavex Life Sciences in the fourth quarter worth $40,000. Finally, BNC Wealth Management LLC increased its stake in shares of Anavex Life Sciences by 19.5% in the fourth quarter. BNC Wealth Management LLC now owns 12,250 shares of the biotechnology company’s stock worth $44,000 after buying an additional 2,000 shares during the period. 31.55% of the stock is owned by institutional investors.

Anavex Life Sciences Company Profile

Anavex Life Sciences Corp is a clinical‐stage biopharmaceutical company focused on the development of novel therapeutics for central nervous system (CNS) disorders. The company applies a proprietary drug discovery platform that targets sigma‐1 and muscarinic receptors to modulate cellular stress pathways and support neuronal function. Headquartered in New York City, Anavex is dedicated to advancing treatments for neurodegenerative and neurodevelopmental diseases with high unmet medical need.

The company’s lead product candidate, blarcamesine (ANAVEX2‐73), is a small‐molecule activator of the sigma‐1 receptor currently being evaluated in clinical trials for Alzheimer’s disease and Parkinson’s disease dementia.